New therapeutic perspectives in prostate cancer – Provenge imunotherapy

Along with progresses in understanding the complex interactions between tumor cells and the immune response of the host and the very dynamic development of genetic engineering techniques, the newer and more efficient immunotherapeutic techniques which generate less secondary effects are gaining more attention when approaching neoplasic pathology. PROVENGE (Sipuleucel-T) falls in this category and it is the first therapeutic cancer vaccine to demonstrate effectiveness in patients who suffer from advanced to the late stage of the disease, asymptomatic, hormone-refractory prostate cancer.